Cyllene Therapeutics SAS has appointed Marc Grasso, MD, as EVP and chief financial officer. He brings more than 28 years of experience in CFO positions at NASDAQ-listed companies and in capital market fundraising. The privately held France-based biotech is developing non-systemic, site-specific therapies for neurological disorders. Its lead DNA medicine candidate EG110A is in a Phase 1b/2a study in the US for neurogenic detrusor overactivity (neurogenic bladder)-related incontinence.
Dr Grasso was most recently CFO of Kyverna Therapeutics Inc and before that at Alector Inc. He was previously CFO and chief business officer of Kura Oncology. At the three companies he oversaw major funding rounds on public markets and coordinated the signing of partnerships and strategic alliances. Dr Grasso also held senior positions in investment banking.
Cyllene Therapeutics announced the appointment on 17 September 2026
Copyright 2026 Evernow Publishing Ltd.